Praluzatamab (CAS: 2145109-70-0)
Praluzatamab is a humanized IgG1 monoclonal antibody that targets ALCAM (CD166), a protein found on various tumor cells.
Key Features:
- Target: Specifically binds to ALCAM/CD166, present on several tumor cells.
- Mechanism: Used to create antibody-drug conjugates (ADCs) for targeted delivery of cytotoxic agents to ALCAM-expressing tumor cells.
- Therapeutic Potential: Investigated for treating cancers like breast cancer.
Applications:
- Cancer Research: Used to develop ADCs targeting ALCAM-expressing tumors, improving treatment precision and reducing side effects.
- ADC Development: Praluzatamab can be used to synthesize Praluzatamab ravtansine, an ADC, for targeted cancer therapy.
- Therapeutic Research: Explored for use in various cancer treatments due to its specificity for ALCAM-expressing cells.
Handling and Storage:
- Storage: Store at -20°C, protected from light.
- Precautions: Use protective equipment and handle in a well-ventilated area.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
